SubsidieMeestersSBMP - disrupting the manufacturing of biological drugs through a ground-breaking nanotechnology-based microcarrier
Cellevate's SBMP-microcarriers use innovative nanofibrous technology to enhance adherent cell culture in bioreactors, significantly improving biopharmaceutical production efficiency and quality.
Projectdetails
Introduction
Cellevate proposes a completely novel type of nanofibrous microcarriers for adherent cell culture in bioreactors based on the proprietary Superior Biologics Manufacturing Platform (SBMP). It is a game-changing deep-tech innovation for the biopharmaceutical industry.
Features of SBMP-Microcarriers
SBMP-microcarriers are:
- Highly customizable
- Faithfully replicate the 3D extracellular environment found in the human body
- Provide a 60 times larger area for cell growth compared to competitive solutions
Technology Behind SBMP-Microcarriers
The unique scaffold properties are a result of a patent-pending nanofiber scaffold production technology (PCT/EP2020/081958) which creates networks of polymer nanofibers that can be handled in a liquid form, unachievable by competing solutions.
Impact on the Biopharmaceutical Market
By offering high yields and ensuring the optimal conditions for human cell growth, SBMP-microcarriers have the potential to transform the biopharmaceutical market by pushing the limits of today’s biological drugs production to an unachievable level of quality and efficiency.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.485.857 |
| Totale projectbegroting | € 3.551.225 |
Tijdlijn
| Startdatum | 1-10-2022 |
| Einddatum | 30-9-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CELLEVATE ABpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Scalable and Eco-friendly BioproductionCore Biogenesis aims to become the European leader in plant-based biomanufacturing by 2025, using a novel process to significantly enhance yield and reduce costs for producing pharmaceutical proteins. | EIC Accelerator | € 1.153.390 | 2023 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
New generation of substrates to harness the full power of microorganismsBac3Gel develops advanced 3D substrates to cultivate complex microbial communities, aiming to discover new antibiotics and bio-based solutions for health and industry challenges. | EIC Accelerator | € 1.500.712 | 2023 | Details |
Scalable and Eco-friendly Bioproduction
Core Biogenesis aims to become the European leader in plant-based biomanufacturing by 2025, using a novel process to significantly enhance yield and reduce costs for producing pharmaceutical proteins.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
New generation of substrates to harness the full power of microorganisms
Bac3Gel develops advanced 3D substrates to cultivate complex microbial communities, aiming to discover new antibiotics and bio-based solutions for health and industry challenges.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Scaling up iPSC Expansion and Differentiation using Recombinant BioemulsionsThe project aims to develop scalable, regulatory-compliant bioemulsions using engineered protein nanosheets for efficient iPSC culture and differentiation, enhancing cell manufacturing and biotech market growth. | ERC Proof of... | € 150.000 | 2025 | Details |
Supramolecular microcapsules for bioreactor expansion of induced pluripotent stem cellsThe SUPROTECT project aims to develop squaramide-based microcapsules for culturing pluripotent stem cells, evaluating their effectiveness while securing intellectual property for potential licensing. | ERC Proof of... | € 150.000 | 2024 | Details |
Biopharmaceuticals purification by continuous membrane-assisted crystallization achieving lower cost and intensified processesThe BIOPURE project aims to revolutionize monoclonal antibody purification using innovative membrane technology to enhance efficiency, reduce costs, and improve access to biomedicines. | EIC Transition | € 2.069.150 | 2023 | Details |
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process controlThe SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors. | EIC Pathfinder | € 1.364.281 | 2022 | Details |
Decellularised Extracellular Carpets for the Innovative Production of Human Engineered ReplicatesThis project aims to accelerate the development of cell-derived products using macromolecular crowding, enhancing European biotech competitiveness and creating new jobs and markets. | ERC Proof of... | € 150.000 | 2024 | Details |
Scaling up iPSC Expansion and Differentiation using Recombinant Bioemulsions
The project aims to develop scalable, regulatory-compliant bioemulsions using engineered protein nanosheets for efficient iPSC culture and differentiation, enhancing cell manufacturing and biotech market growth.
Supramolecular microcapsules for bioreactor expansion of induced pluripotent stem cells
The SUPROTECT project aims to develop squaramide-based microcapsules for culturing pluripotent stem cells, evaluating their effectiveness while securing intellectual property for potential licensing.
Biopharmaceuticals purification by continuous membrane-assisted crystallization achieving lower cost and intensified processes
The BIOPURE project aims to revolutionize monoclonal antibody purification using innovative membrane technology to enhance efficiency, reduce costs, and improve access to biomedicines.
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process control
The SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors.
Decellularised Extracellular Carpets for the Innovative Production of Human Engineered Replicates
This project aims to accelerate the development of cell-derived products using macromolecular crowding, enhancing European biotech competitiveness and creating new jobs and markets.